{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:03:15Z","timestamp":1790082195743,"version":"4.0.1"},"reference-count":25,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Frontline Gastroenterol"],"accepted":{"date-parts":[[2023,5,31]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:p>Hepatitis B virus and hepatitis C virus (HCV) remain leading causes of disability and premature death worldwide. In May 2016, the UK, as a member of the World Health Assembly, adopted the Global Health Sector Strategy and its targets to eliminate viral hepatitis as a public health threat by 2030. In pursuit of this goal, there have been a number of recent advances in viral hepatitis care. Perhaps most notable is the availability of short courses of all-oral curative direct acting antivirals for hepatitis C. However, while access to treatment has been scaled up across the UK, an estimated 93\u2009000 people were still living with HCV at the end of 2021 of which three-quarters remained unaware of their infection.<\/jats:p>\n               <jats:p>This review article will summarise key advances in hepatitis C treatment and prevention and provide a practical approach to the management of individuals living with hepatitis C infection.<\/jats:p>","DOI":"10.1136\/flgastro-2022-102373","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T13:21:11Z","timestamp":1686662471000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Hepatitis C: recent advances and practical management"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6844-0596","authenticated-orcid":false,"given":"Rebecca","family":"O' Kane","sequence":"first","affiliation":[{"name":"Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Hathorn","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"2025090708015195000_14.5.415.1","unstructured":"World Health Organization . Global hepatitis report; 2017."},{"key":"2025090708015195000_14.5.415.2","unstructured":"UKHSA . Hepatitis C in the UK 2023 Working to eliminate hepatitis C as a public health threat."},{"key":"2025090708015195000_14.5.415.3","unstructured":"UKHSA . Hepatitis C in England 2022 Working to eliminate hepatitis C as a public health problem: Short report."},{"key":"2025090708015195000_14.5.415.4","unstructured":"NICE Hepatitis B and C testing: people at risk of infection . Public health guideline [Ph43]. 2012."},{"key":"2025090708015195000_14.5.415.5","unstructured":"WHO . Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016 to 2021: actions for impact."},{"key":"2025090708015195000_14.5.415.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26164"},{"key":"2025090708015195000_14.5.415.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2015.07.003"},{"key":"2025090708015195000_14.5.415.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"2025090708015195000_14.5.415.9","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/v13081580","article-title":"SHARED: an international collaboration to unravel hepatitis C resistance, viruses","volume":"13","author":"Howe","year":"2021","journal-title":"Viruses"},{"key":"2025090708015195000_14.5.415.10","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/infdis\/jiab110","article-title":"Real-world outcomes of direct-acting antiviral treatment and Retreatment in United Kingdom\u2013based patients infected with hepatitis C virus Genotypes\/subtypes Endemic in Africa","volume":"226","author":"Aranday-Cortes","year":"2022","journal-title":"J Infect Dis"},{"key":"2025090708015195000_14.5.415.11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24105"},{"key":"2025090708015195000_14.5.415.12","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.4103\/jfmpc.jfmpc_666_21","article-title":"APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection","volume":"10","author":"Rungta","year":"2021","journal-title":"J Family Med Prim Care"},{"key":"2025090708015195000_14.5.415.13","unstructured":"HEP Drug Interactions . Interaction checker. University of Liverpool, Available: https:\/\/www.hep-druginteractions.org\/"},{"key":"2025090708015195000_14.5.415.14","unstructured":"Hydar El J . Protease inhibitors (PI) in treatment of hepatitis C and the risk of Hepaticdecompensation: a systematic review of all PI use vs Sofosbuvir + Ns5A inhibitor +\/- ribavirin,AASLD. 2021."},{"key":"2025090708015195000_14.5.415.15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to Sofosbuvir and Velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025090708015195000_14.5.415.16","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw676"},{"key":"2025090708015195000_14.5.415.17","doi-asserted-by":"crossref","unstructured":"Drysdale K et al . DAA effectiveness in England: high response rates in GT 3 HCV infection regardless of degree of fibrosis, but RBV improves response in cirrhosis. ILC 2019:LB\u201308. doi:10.1016\/S0618-8278(19)30231-2","DOI":"10.1016\/S0618-8278(19)30231-2"},{"key":"2025090708015195000_14.5.415.18","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13022"},{"key":"2025090708015195000_14.5.415.19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/hep.28926","article-title":"Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list","volume":"65","author":"Chhatwal","year":"2017","journal-title":"Hepatology"},{"key":"2025090708015195000_14.5.415.20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jhep.2021.01.046","article-title":"Antiviral therapy in the palliative setting of HCC [BCLC-B and-C]","volume":"74","author":"Reig","year":"2021","journal-title":"J Hepatol"},{"key":"2025090708015195000_14.5.415.21","unstructured":"British Viral Hepatitis Group . UK Position Statement on the use of Organs from Hepatitis C Viraemic Donors and Increased Infectious Risk Donors in Hepatitis C Negative Recipients."},{"key":"2025090708015195000_14.5.415.22","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jhep.2020.11.014","article-title":"Hepatitis C Viraemic organs in solid organ transplantation","volume":"74","author":"Weinfurtner","year":"2021","journal-title":"J Hepatol"},{"key":"2025090708015195000_14.5.415.23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hep.32341","article-title":"HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A Meta\u2010Analysis","volume":"76","author":"Lockart","year":"2022","journal-title":"Hepatology"},{"key":"2025090708015195000_14.5.415.24","unstructured":"UKHSA . Unlinked anonymous monitoring (UAM) survey of HIV and viral hepatitis among PWID: 2022 report."},{"key":"2025090708015195000_14.5.415.25","unstructured":"World Health Organisation . Updated recommendations on treatment of adolescents and children with chronic HCV infection and HCV simplified service delivery and diagnostics. 2022."}],"container-title":["Frontline Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/flgastro-2022-102373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:02:04Z","timestamp":1757257324000},"score":1,"resource":{"primary":{"URL":"https:\/\/fg.bmj.com\/lookup\/doi\/10.1136\/flgastro-2022-102373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,8,7]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/flgastro-2022-102373"],"URL":"https:\/\/doi.org\/10.1136\/flgastro-2022-102373","relation":{},"ISSN":["2041-4137","2041-4145"],"issn-type":[{"value":"2041-4137","type":"print"},{"value":"2041-4145","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]}}}